{"meta":{"query_hash":"5756479a69f8","filters":{"venue":"Journal of Drug Assessment"},"cohort_total":5,"direct_labels_cover":0,"predictions_cover":5,"exported":5,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/5756479a69f8","api":"https://metacan.xera.ac/api/v1/cohort?venue=Journal+of+Drug+Assessment"},"results":[{"id":"W2049723660","doi":"10.3109/21556660.2013.792823","title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus","year":2013,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Systemic Lupus Erythematosus Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Commission","keywords":"Belimumab; Medicine; Tolerability; Pharmacokinetics; Adverse effect; Placebo; Pharmacodynamics; Pharmacology; Dosing; Internal medicine; B-cell activating factor; Immunology; Antibody; B cell; Pathology","score_opus":0.010960612834359541,"score_gpt":0.3053165700250582,"score_spread":0.2943559571906986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2049723660","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972078,0.002137948,0.0001718645,0.00009031722,0.000006465964,0.000035872166,0.000035432775,0.000008561544,0.00030572605],"genre_scores_gemma":[0.99916637,0.00041546256,0.00015985874,0.0000924083,0.000012552416,0.000019782556,0.000036623605,0.0000010964727,0.00009589059],"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.9996917,0.00014524606,0.00003732462,0.000033891432,0.00005782571,0.00003409398],"domain_scores_gemma":[0.9995919,0.000074027055,0.00015212967,0.000019928026,0.00004665036,0.00011540593],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007978213,0.00024960111,0.00060372293,0.00011702799,0.00026753638,0.00023611014,0.00010816564,0.00021146718,0.00055383076],"category_scores_gemma":[0.00079702423,0.00015449678,0.00031336182,0.0001674398,0.00025853683,0.00020687704,0.00016562639,0.00035695347,0.00012647],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15113305,0.006560513,0.44104263,0.0027102667,0.0022494788,0.00131456,0.002174076,0.0015871235,0.16403893,0.00018963423,0.0019075727,0.22509223],"study_design_scores_gemma":[0.012844579,0.1088031,0.8619674,0.000111316884,0.001573533,0.002434007,0.0004877289,0.0015826132,0.0056428146,0.00014583679,0.004344631,0.00006238549],"about_ca_topic_score_codex":0.0008982709,"about_ca_topic_score_gemma":0.0020164857,"teacher_disagreement_score":0.0008982709,"about_ca_system_score_codex":0.0002550091,"about_ca_system_score_gemma":0.00035376812,"threshold_uncertainty_score":0.004219353},"labels":[],"label_agreement":null},{"id":"W2604901999","doi":"10.1080/21556660.2017.1315336","title":"Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma","year":2017,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"CD22; Medicine; Refractory (planetary science); Calicheamicin; Lymphoma; Internal medicine; Oncology; CD20","score_opus":0.015372535247445678,"score_gpt":0.3181207012641905,"score_spread":0.3027481660167448,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2604901999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99651176,0.0011620607,0.00032530027,0.0001597419,0.000040527673,0.00093009055,0.0002292404,0.000045137953,0.0005962704],"genre_scores_gemma":[0.9953916,0.0010849411,0.00092100503,0.00028712157,0.00007868038,0.00082517386,0.000646651,0.000015496575,0.0007493457],"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99967813,0.00016371085,0.000014490724,0.000056467103,0.00003372917,0.00005338993],"domain_scores_gemma":[0.99964774,0.00005082905,0.000084694366,0.000030791412,0.000023730376,0.00016224055],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010239708,0.0011481544,0.0018158297,0.00030971217,0.0003199836,0.0007075715,0.0007335089,0.0006866509,0.0016297493],"category_scores_gemma":[0.00061534636,0.0004762282,0.0006963826,0.0002719772,0.0006741449,0.0005685523,0.00028744078,0.0020581323,0.00046262407],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49149635,0.115179926,0.016022671,0.0015508255,0.0025756285,0.00092590996,0.00082928134,0.005477171,0.16938807,0.00038822493,0.0042398935,0.19192609],"study_design_scores_gemma":[0.35674655,0.6057998,0.019496828,0.00004704341,0.00071631046,0.0005912547,0.00007493666,0.0017233304,0.011337777,0.000102690145,0.0033324594,0.00003101082],"about_ca_topic_score_codex":0.0007619043,"about_ca_topic_score_gemma":0.0022903667,"teacher_disagreement_score":0.0018158297,"about_ca_system_score_codex":0.0007646114,"about_ca_system_score_gemma":0.0011756395,"threshold_uncertainty_score":0.0055476427},"labels":[],"label_agreement":null},{"id":"W2972150441","doi":"10.1080/21556660.2019.1658313","title":"Understanding purchasing patterns and product access of newly launched specialty generics","year":2019,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Quarter (Canadian coin); Product (mathematics); Purchasing; Pharmacy; Launched; Specialty; Marketing; Business; Medicine; Advertising; Family medicine; Engineering","score_opus":0.16158098750113523,"score_gpt":0.3508699535733115,"score_spread":0.1892889660721763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2972150441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.952678,0.006180619,0.00090628717,0.0073405695,0.00004833262,0.000021474074,0.028272087,0.000020571551,0.0045321016],"genre_scores_gemma":[0.97917557,0.0030591646,0.0014089277,0.00067149586,0.00008171686,0.000022960774,0.013973104,0.000007957857,0.0015991483],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9996995,0.00007246263,0.000037077065,0.000059596136,0.00008252905,0.000048898055],"domain_scores_gemma":[0.99609536,0.0014178925,0.0016029896,0.00012088311,0.00037684452,0.00038590183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012075641,0.00022448527,0.00023543688,0.0012699692,0.00020756402,0.0009923796,0.0003896503,0.00055407075,0.004541763],"category_scores_gemma":[0.005891973,0.000222992,0.0005829092,0.0026113705,0.0001624403,0.0016119167,0.0007116005,0.00081289315,0.0010033145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00016837618,0.00008899164,0.9426602,0.00008078315,0.00016210657,0.00008190996,0.00034124625,0.0006933641,0.00017095514,0.00072679395,0.008447844,0.046377465],"study_design_scores_gemma":[0.000010418764,0.00007484702,0.9900315,0.00007660561,0.000085397565,0.00011855589,0.0005530407,0.0026150427,0.000110996734,0.0011473699,0.0051649376,0.000011349503],"about_ca_topic_score_codex":0.04256643,"about_ca_topic_score_gemma":0.06799283,"teacher_disagreement_score":0.04256643,"about_ca_system_score_codex":0.00071897503,"about_ca_system_score_gemma":0.00072015007,"threshold_uncertainty_score":0.084637284},"labels":[],"label_agreement":null},{"id":"W2980673510","doi":"10.1080/21556660.2019.1678478","title":"The effectiveness and safety of pharmaceuticals to manage excess weight post-bariatric surgery: a systematic literature review","year":2019,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Bariatric Surgery and Outcomes","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Maple Leaf Medical Clinic; York University","funders":"","keywords":"Medicine; Weight loss; Phentermine; Topiramate; Weight management; Placebo; Surgery; Randomized controlled trial; Obesity; Weight Loss Surgery; Gastric bypass surgery; Cochrane Library; Gastric bypass; Internal medicine; Alternative medicine","score_opus":0.009661768118087525,"score_gpt":0.3224925958930861,"score_spread":0.3128308277749986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980673510","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015226823,0.99736136,0.00008837513,0.00021129767,0.00007696022,0.00023452935,0.0002937749,0.000005436899,0.00020551946],"genre_scores_gemma":[0.019171037,0.97864884,0.0006486477,0.0006216989,0.00010300711,0.00047029532,0.00024024582,0.00000486998,0.00009133516],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99157166,0.0024030036,0.0037797096,0.0005500864,0.0014947252,0.0002008186],"domain_scores_gemma":[0.9659187,0.023207527,0.0075476966,0.00037988793,0.0026154262,0.0003306661],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006982974,0.0013097721,0.0072221677,0.011933123,0.00069577066,0.0024705224,0.0016608933,0.002193832,0.0034177012],"category_scores_gemma":[0.03857757,0.001012358,0.0072724554,0.009435893,0.0008982457,0.0021783651,0.0013376513,0.0010920402,0.0002512802],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001786061,0.000019321826,0.0009828757,0.9664914,0.008910003,0.00009977665,0.00013273611,0.000046399164,0.00011638014,0.00009479024,0.0006986892,0.02222907],"study_design_scores_gemma":[0.00030273938,0.00036236338,0.0058163553,0.88896734,0.09105159,0.00060694804,0.00034159652,0.000074092895,0.00021260678,0.00019605298,0.0120304795,0.000037881327],"about_ca_topic_score_codex":0.005362065,"about_ca_topic_score_gemma":0.01861562,"teacher_disagreement_score":0.011933123,"about_ca_system_score_codex":0.0028552944,"about_ca_system_score_gemma":0.010355087,"threshold_uncertainty_score":0.036929905},"labels":[],"label_agreement":null},{"id":"W3116289745","doi":"10.1080/21556660.2020.1854561","title":"Exploring the burden of short-term CHOP chemotherapy adverse events in post-transplant lymphoproliferative disease: a comprehensive literature review in lymphoma patients","year":2020,"lang":"en","type":"article","venue":"Journal of Drug Assessment","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Atara Biotherapeutics","keywords":"Medicine; Adverse effect; Lymphoproliferative disease; Lymphoma; Rituximab; CHOP; Chemotherapy; Disease; Lymphoproliferative disorders; Internal medicine; Oncology; Intensive care medicine","score_opus":0.024222801345273052,"score_gpt":0.2976380105352367,"score_spread":0.27341520918996365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3116289745","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019512617,0.99642986,0.00011710059,0.0004281679,0.00007561008,0.00013865702,0.0005181603,0.0000046080986,0.00033662596],"genre_scores_gemma":[0.020431772,0.9776804,0.0005241204,0.00059812714,0.00010243127,0.00026708527,0.00031864448,0.0000047834837,0.000072667215],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.99201375,0.0021298295,0.0039058463,0.00050568837,0.0012188538,0.0002261121],"domain_scores_gemma":[0.9544505,0.033611465,0.0073130364,0.00049511297,0.0037664322,0.0003634771],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00915384,0.0010564126,0.0050511407,0.020418284,0.0006454379,0.00297691,0.001429725,0.0018415563,0.003615572],"category_scores_gemma":[0.038036034,0.0007995028,0.0068320874,0.017711304,0.0007211049,0.0022116865,0.0015297019,0.0009993984,0.00025290018],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020902997,0.000025126032,0.0023648762,0.9333693,0.009312984,0.0002537477,0.00035731273,0.00015937809,0.00021822538,0.00036762145,0.001842958,0.051519558],"study_design_scores_gemma":[0.00011395728,0.00025563478,0.010704822,0.8893271,0.07114122,0.0010824862,0.0006441535,0.00013502172,0.0002086144,0.00053284934,0.025804903,0.0000491966],"about_ca_topic_score_codex":0.0061499747,"about_ca_topic_score_gemma":0.015358014,"teacher_disagreement_score":0.020418284,"about_ca_system_score_codex":0.00311943,"about_ca_system_score_gemma":0.009874698,"threshold_uncertainty_score":0.048410714},"labels":[],"label_agreement":null}]}